Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorin e6-heptamethine cyanine conjugate
- Development stage
- Preclinical
- Lead developer
- Cedars-Sinai
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Chlorin e6-heptamethine cyanine conjugate is a tumor-targeting photosensitizer-carrier conjugate (PSC) developed as a multifunctional theranostic agent for cancer imaging and photodynamic therapy. The conjugate is synthesized by attaching chlorin e6 (Ce6), a photosensitizer, to a heptamethine cyanine dye derivative (such as MHI-148 or IR-783). The heptamethine cyanine dye component selectively targets and accumulates within cancer cells by utilizing organic anion-transporting polypeptides (OATPs) and hypoxia-induced factors, overcoming the lack of tumor specificity of free chlorin e6. These conjugates can be complexed with copper isotopes (such as radioactive copper-64) to enable quantitative PET imaging and radiotherapeutic applications, while also allowing near-infrared fluorescence (NIRF) imaging and photodynamic therapy (PDT) upon light activation.
- Other names
- chlorin e6 heptamethine cyanine conjugatechlorin e6 heptamethine cyanine conjugateschlorin e6-heptamethine cyanine conjugates
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)OATP (Organic anion transporting polypeptides)
Beyond the preview
Go deeper on chlorin e6-heptamethine cyanine conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorin e6-heptamethine cyanine conjugate.